Abstract
Opioid peptides and their G protein-coupled receptors (GPCRs) are important regulators within the cardiovascular system, implicated in modulation of electrophysiological function, heart rate, myocardial inotropy, vascular function, and cellular stress resistance. The opioid system is also involved in cardiovascular development, adaptation to injury and effects of advanced age. The significant roles of opioids are emphasized by the observation that the heart produces prodynorphin and proenkephalin, which are enzymatically processed from small to large active polypeptides. Indeed, depending on species, cardiac preproenkephalin mRNA levels are comparable to or higher than those found in the central nervous system. This review highlights and discusses current knowledge and recent findings regarding physiological and pathophysiological modulation of the heart and vessels by the opioid receptor system.
Keywords: Opioid peptide, opioid receptor, cardiovascular system, cytoprotection, G protein-coupled receptors (GPCRs), electrophysiological function, heart rate, myocardial inotropy, vascular function, cellular stress resistance.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Volume: 18 Issue: 37
Author(s): John P. Headrick, Salvatore Pepe and Jason N. Peart
Affiliation:
Keywords: Opioid peptide, opioid receptor, cardiovascular system, cytoprotection, G protein-coupled receptors (GPCRs), electrophysiological function, heart rate, myocardial inotropy, vascular function, cellular stress resistance.
Abstract: Opioid peptides and their G protein-coupled receptors (GPCRs) are important regulators within the cardiovascular system, implicated in modulation of electrophysiological function, heart rate, myocardial inotropy, vascular function, and cellular stress resistance. The opioid system is also involved in cardiovascular development, adaptation to injury and effects of advanced age. The significant roles of opioids are emphasized by the observation that the heart produces prodynorphin and proenkephalin, which are enzymatically processed from small to large active polypeptides. Indeed, depending on species, cardiac preproenkephalin mRNA levels are comparable to or higher than those found in the central nervous system. This review highlights and discusses current knowledge and recent findings regarding physiological and pathophysiological modulation of the heart and vessels by the opioid receptor system.
Export Options
About this article
Cite this article as:
P. Headrick John, Pepe Salvatore and N. Peart Jason, Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582360
DOI https://dx.doi.org/10.2174/138161212803582360 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
Current Medicinal Chemistry Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Diabetic Cardiomyopathy: From Mechanism to Management in a Nutshell
Endocrine, Metabolic & Immune Disorders - Drug Targets Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Role of Non-Coding RNA of Human Platelet in Cardiovascular Disease
Current Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Cardiolipin Metabolism and the Role it Plays in Heart Failure and Mitochondrial Supercomplex Formation
Cardiovascular & Hematological Disorders-Drug Targets Diabetes and Metallothionein
Mini-Reviews in Medicinal Chemistry